These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 39007954)
1. Unveiling the intricacies of COVID-19: Autoimmunity, multi-organ manifestations and the role of autoantibodies. Ding Z; Wei X; Pan H; Shi H; Shi Y Scand J Immunol; 2024 Feb; 99(2):e13344. PubMed ID: 39007954 [TBL] [Abstract][Full Text] [Related]
2. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Vojdani A; Vojdani E; Kharrazian D Front Immunol; 2020; 11():617089. PubMed ID: 33584709 [TBL] [Abstract][Full Text] [Related]
3. Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement. Mohkhedkar M; Venigalla SSK; Janakiraman V Mol Immunol; 2021 Sep; 137():105-113. PubMed ID: 34242919 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection as a trigger of autoimmune response. Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235 [TBL] [Abstract][Full Text] [Related]
5. Autoimmune complications of COVID-19. Yazdanpanah N; Rezaei N J Med Virol; 2022 Jan; 94(1):54-62. PubMed ID: 34427929 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 and autoimmune diseases. Liu Y; Sawalha AH; Lu Q Curr Opin Rheumatol; 2021 Mar; 33(2):155-162. PubMed ID: 33332890 [TBL] [Abstract][Full Text] [Related]
7. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes. Moody R; Sonda S; Johnston FH; Smith KJ; Stephens N; McPherson M; Flanagan KL; Plebanski M Front Immunol; 2022; 13():945021. PubMed ID: 36032086 [TBL] [Abstract][Full Text] [Related]
9. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. Vahabi M; Ghazanfari T; Sepehrnia S Int Immunopharmacol; 2022 Nov; 112():109183. PubMed ID: 36182877 [TBL] [Abstract][Full Text] [Related]
12. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. Dalakas MC; Bitzogli K; Alexopoulos H Front Immunol; 2021; 12():627285. PubMed ID: 33679770 [No Abstract] [Full Text] [Related]
14. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
15. Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies. Haberland A; Krylova O; Nikolenko H; Göttel P; Dallmann A; Müller J; Weisshoff H Viruses; 2021 May; 13(5):. PubMed ID: 34069827 [TBL] [Abstract][Full Text] [Related]
16. Adaptive Immunity and the Risk of Autoreactivity in COVID-19. Moody R; Wilson K; Flanagan KL; Jaworowski A; Plebanski M Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445670 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1. Pagano S; Yerly S; Meyer B; Juillard C; Suh N; Le Terrier C; Daguer JP; Farrera-Soler L; Barluenga S; Piumatti G; Hartley O; Lemaitre B; Eberhardt CS; Siegrist CA; Eckerle I; Stringhini S; Guessous I; Kaiser L; Pugin J; Winssinger N; Vuilleumier N Eur J Clin Invest; 2021 Nov; 51(11):e13661. PubMed ID: 34324704 [TBL] [Abstract][Full Text] [Related]